Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion on August 05, 2025 Acute onset pain Approved Drug Development Journavx non-opioid pain drugs Pain management Peripheral neuropathic pain Sodium Channel Blockers United States Food and Drug Administration VX-993 +
Praxis Seizure Drug Vormatrigine Shows Strong Efficacy in Phase 2 Trial on August 05, 2025 Clinical Research Epilepsy focal onset seizures Praxis Precision Medicines Radiant heater Seizures Sodium Channel Blockers vormatrigine +